Peri-liver transplant hyperglycemia.
Conditions
Interventions
Intervention 1: Control group: Blood glucose control according to current protocol. Intervention 2: Intervention group: Blood glucose control based on a targeted pharmacotherapy protocol.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Liver transplant recipients aged 18 to 65 years Deceased donor liver transplant Blood glucose level higher than 140 mg/dL intraoperatively/postoperatively (with or without a history of diabetes)
Exclusion criteria
Exclusion criteria: Recent surgery within the past 30 days before the transplant Multi-organ transplant recipients Participate in other interventional clinical trials simultaneously
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of blood glucose control using a targeted pharmacotherapy protocol compared to current protocol. Timepoint: Blood glucose measurement at baseline, during hospitalization (during ICU stay in the pre-protocol phase every 6 hours and in the protocol phase every 1 to 4 hours; during hospitalization in the ward, fasting, before lunch, before dinner, and at bedtime) and after discharge on days 15, 30, 60, and 90. Method of measurement: Blood test (venous blood glucose level) or glucometer (capillary blood glucose level). | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of targeted pharmacotherapy protocol with current protocol on the incidence of any infection in liver transplant recipients within 3 months after transplantation. Timepoint: During hospitalization and after discharge on days 15, 30, 60, and 90. Method of measurement: Based on the criteria for each infection, positive culture, antibiotic regimen for more than 3 days, and confirmation by the infectious disease service.;Comparison of targeted pharmacotherapy protocol with current protocol on mechanical ventilation in liver transplant recipients during hospitalization. Timepoint: During hospitalization. Method of measurement: Patient's medical records.;Comparison of targeted pharmacotherapy protocol with current protocol on length of hospitalization in liver transplant recipients. Timepoint: During hospitalization. Method of measurement: Patient's medical records.;Comparison of targeted pharmacotherapy protocol with current protocol on the incidence of acute kidney injury or need for dialysis in liver transplant recipients within 3 months after transplantation. Timepoint: During hospitalization and after discharge on days 15, 30, 60, and 90. Method of measurement: KDIGO criteria.;Comparison of targeted pharmacotherapy protocol with current protocol on the incidence of graft rejection in liver transplant recipients within 3 months after transplantation. Timepoint: During hospitalization and after discharge on days 15, 30, 60, and 90. Method of measurement: An unexplained two times or more of AST/ALT and normalization following 3 days of pulse methylprednisolone, definitive diagnosis and severity of graft rejection by liver biopsy and using Banff criteria.;Comparison of targeted pharmacotherapy protocol with current protocol on the incidence of new-onset diabetes after transplantation in liver transplant recipients. Timepoint: During hospitalization and after discharge on days 15, 30, 60, and 90. Method of measurement: blood glucose level.;Comparison of targete | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactYekta Rameshi
Tehran University of Medical Sciences
Outcome results
None listed